This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
The sequence carries three residues in the order glycine, histidine, lysine, which places a small, flexible chain around a single metal centre. Compared with larger copper-binding proteins, the complex is compact and its coordination chemistry can be reproduced with synthetic peptide in a laboratory. Published structural work agrees on the nitrogen donor set but differs in the exact geometry assigned under some conditions, so the arrangement is best treated as well characterised in outline rather than fixed in every detail.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C for solid; 2-8 °C for short-term solution use | Avoid repeated freeze-thaw cycles |
| Preferred solvent | Water or aqueous buffer near neutral pH | Nonpolar solvents give poor dissolution |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Copper quantified separately by ICP-MS |
| Principal degradation routes | Backbone hydrolysis, histidine oxidation, photolysis | Alkaline pH accelerates hydrolysis |
| Counterion form | Acetate salt is common | Counterion contributes to measured mass |
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Cyprodime is a selective MOR antagonist Naltrindole is a selective DOR antagonist Norbinaltorphimine is a selective KOR antagonist J-113,397 is a selective nociceptin receptor (NOP) antagonist Other selective antagonists are also known, but the four listed above were the first selective antagonists discovered for each respective opioid receptor, and are still the most widely used. In addition to selective antagonists, AT-076 is a non-selective, balanced antagonist of all four of the opioid receptors, and was the first such agent to be discovered.
Flip–flop kinetics, or flip–flop pharmacokinetics, describes an atypical situation in pharmacokinetics where a drug's rate of absorption or the rate at which it enters the bloodstream is slower than its elimination rate. That is, when the ka (absorption constant) is slower than ke (elimination constant). These circumstances can occur with sustained-release formulations, depot injections, and some subcutaneous or intradermal injections. In the resulting slope of log plasma concentration (log Cp) versus time, the apparent ke is determined by the ka, and the apparent ke is smaller than when the drug is administered intravenously or by immediate-release formulation. Depot injections such as depot antipsychotics and long-acting injectable steroid hormone medications like estradiol valerate, testosterone enanthate, and medroxyprogesterone acetate are examples of drugs with flip–flop kinetics. The term "flip–flop" indicates that the downward slope more closely represents ka rather than ke. Flip–flop kinetics can create difficulties in the determination and interpretation of pharmacokinetic parameters if not recognized.
These pedestrian zones are part of an effort to combat chronic diseases, including obesity. In an effort to combat the issue, a primary school in Australia instituted a standing classroom in 2013. There is evidence that exercise alone is not sufficient to produce meaningful weight loss, but combining dieting and exercise provide the greatest health benefits and weight loss on the long term.
== Academic career and scientific contributions == Beutler pursued a remarkably eclectic research career, and made fundamental contributions in many different areas of science over 56 years of active publication. His first scientific paper was published in 1952, and concerned the effect of X-irradiation on susceptibility to influenza virus in mice. This was an attempt to determine whether irradiated mice might offer a better experimental model in which to detect human viral infections. Not long afterward, he published a paper on the lag phase of E. coli, which is also influenced by X-irradiation. This work, carried out during his residency in the laboratory of Leon O. Jacobson, was aimed at the development of an assay for a humoral radioprotective factor, and reflected a chance observation. Beutler also developed an early interest in iron metabolism, prompted by his clinical observation of the rapid symptomatic improvement of iron deficient patients treated with iron: an improvement that preceded any major hematologic change, and showed that numerous enzymes were sensitive to iron deficiency. After completing his residency (1953), Beutler applied for a commission as a lieutenant in the U.S. Army, and was assigned to the Army Malaria Research Program. During this period, he worked at Joliet Prison in Illinois (1953–1954), investigating anemia produced by antimalarial drugs. In the course of his work, he identified glucose-6-phosphate dehydrogenase (G-6-PD) deficiency as a genetic defect that leads to the lysis of red blood cells under conditions of oxidative stress.
According to The Economist, "All this makes the most sense if the principal intent is to rattle Mr Maduro, give succour to Venezuela's opposition or even stir an uprising within the Venezuelan armed forces—encouraged perhaps by that recently doubled reward." Experts speaking to Reuters and the BBC described the deployment as gunboat diplomacy and Trump administration sources stated a likely goal was to pressure the Maduro administration. James G. Stavridis, a former US Navy admiral, characterized the strike and other US military activity around the same time as gunboat diplomacy intended to demonstrate the vulnerability of Venezuelan oil rigs and materiel. He wrote that drug interdiction was likely not the sole reason for the increased US military activity. The New York Times reported that a group of officials, led by US National Security Advisor and Secretary of State Marco Rubio, was pushing for a military campaign that would drive Maduro from power. Members of Venezuela's opposition told the New York Times they have coordinated with the Trump administration on a plan for the first hundred hours after Maduro's deposition. PBS News reported that Trump was using the military to counter cartels he blamed for trafficking fentanyl and other illicit drugs into the US and for fuelling violence in American cities, stating that the government had "not signaled any planned land incursion"—similarly, The Guardian stated that "many experts are skeptical the US is planning a military intervention" in Venezuela.
Sources: en.wikipedia.org
Paclitaxel (Taxol) total synthesis: First synthesized by Robert A. Holton in 1994, and later by K. C. Nicolaou in 1995, this anticancer drug's synthesis was a major breakthrough in medicinal chemistry. Brefeldin A: Synthesized by S. Raghavan in 2017, this complex macrolide has potential as an anticancer agent. Ryanodine: Synthesized by Sarah E. Reisman in 2017, this complex diterpenoid has important biological activity.
=== Dependence === Opioid dependence can occur as physical dependence, psychological dependence, or both. Drug dependence is an adaptive state associated with a withdrawal syndrome upon cessation of repeated exposure to a stimulus (e.g., drug intake). Dependence is a component of a substance use disorder. Opioid dependence can manifest as physical dependence, psychological dependence, or both. Increased brain-derived neurotrophic factor (BDNF) signaling in the ventral tegmental area (VTA) has been shown to mediate opioid-induced withdrawal symptoms via downregulation of insulin receptor substrate 2 (IRS2), protein kinase B (AKT), and mechanistic target of rapamycin complex 2 (mTORC2). As a result of downregulated signaling through these proteins, opiates cause VTA neuronal hyperexcitability and shrinkage (specifically, the size of the neuronal soma is reduced). It has been shown that when an opiate-naive person begins using opiates in concentrations that induce euphoria, BDNF signaling increases in the VTA. Upregulation of the cyclic adenosine monophosphate (cAMP) signal transduction pathway by cAMP response element binding protein (CREB), a gene transcription factor, in the nucleus accumbens is a common mechanism of psychological dependence among several classes of drugs of abuse. Upregulation of the same pathway in the locus coeruleus is also a mechanism responsible for certain aspects of opioid-induced physical dependence. A scale was developed to compare the harm and dependence liability of 20 drugs.
1-Iodomorphine is a semi-synthetic narcotic analgesic formed by halogenation of the 1 position on the morphine carbon skeleton. Halogenated morphine derivatives were first synthesised in Germany, Austria/Austria-Hungary, the United Kingdom and the United States in the period 1890 to 1930. Use of this drug increased after 1945 for the below-mentioned research. It is a research chemical which is often prepared in the laboratory when it is needed. Along with the similar 2-iodomorphine as well as iodinated analogs of dihydromorphine, dihydrocodeine, heroin, and the fluorinated, chlorinated, and brominated analogues of this series, this change may not impact the activity of the drug to a notable extent but 1- and 2-iodomorphine are used in pharmacological, neurological, metabolic, and endocrine research as it allows the tagging of morphine with iodine-131 or iodine-129. Such research was important in the discovery of opioid receptors in the central nervous system, peripheral nervous system, and other tissues in humans, mammals, birds, and some reptiles, amphibians, fish, insects, and arthropods.
CP, Crude protein; NRC MR, National Research Council Minimal Requirement; NR, not required (taurine not an essential amino acid in the dog); NA, not adequate sample for analysis Amino acids measured on a mg/g DM basis The results demonstrated that all evaluated insects met the canine and feline MR for growth of the NRC for EAA and CP with exception to the black soldier fly in regards to taurine, where composition was lower than recommended.
Sources: en.wikipedia.org
The solid is typically held cold and dry, and solutions are kept for shorter periods because hydrolysis proceeds in water. Repeated freeze-thaw cycles are usually avoided, since they can degrade both the peptide and the complex. Container material and headspace also affect how long a sample remains unchanged.
Copper is quantified by an elemental technique such as inductively coupled plasma mass spectrometry, not by peptide chromatography. The chromatographic result describes the peptide chain, while the elemental result describes the metal. Reporting both is what makes the stoichiometry checkable.
It normally lists the analytical methods used, the measured purity, the appearance, and any residuals or counterions detected. It is a statement about a specific batch rather than a general property of the material. Independent testing is still needed when results must be traceable to a reference standard.
It consists of a three-amino-acid peptide, glycine-histidine-lysine, bound to one copper(II) ion. The peptide supplies four nitrogen donor atoms, and the resulting complex is stable in neutral aqueous solution. The metal-free peptide is usually called GHK.